The information you provide herein will be used to create the LabCorp account under which testing services for the Sanofi Genzyme Specialty Rare Disease Testing Program will be placed and results delivered.  Testing services will transition to LabCorp on December 16, 2019. Should you have any questions regarding the current biomarker and immunogenicity testing program, please contact Genzyme Clinical Specialty Laboratory (CSL).

By creating an account, I certify that we are not listed on any sanctions list published by the U.S. Departments of Commerce, Treasury, or State, including, but not limited to, the Specially Designated Nationals and Blocked Persons List and the Denied Persons List.